CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
When faced with unexpected expenses, prioritize essentials, tap your emergency buffers, and reallocate discretionary funds. A clear action plan minimizes impact fast.
9,452 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
A fresh government outlook puts social security's insolvency date at the end of 2032, prompting talks of payroll tax ...
Two popular energy ETFs sit on opposite ends of the spectrum: XLE, focused on US fossil fuels, and ICLN, targeting gl...
New U.S. vital statistics show a continued drop in births. The trend arrives as smartphones saturate households and l...
SpaceX is courting attention ahead of a potential Nasdaq debut. Some ETFs offer pre-IPO exposure via SPVs, but the st...
As households face ongoing economic pressure in 2026, divorce can ripple through finances for years. This report outl...
A new PwC assessment finds AI tools in health care are expanding billing detail and potentially lifting the supposed ...
Trump signals a deal with Iran could be signed this weekend, but Tehran cautions that no final agreement exists. Medi...
Rent is due on the first, but most workers are paid on varied schedules. A growing body of data points to a hidden co...
JPMorgan's Nasdaq Equity Premium Income ETF offers a high monthly yield around 10% but carries equity risk. This arti...
A pivotal day is on the horizon. This guide helps investors understand what to watch, how to react, and practical ste...
Investors are eyeing a steady cash flow from dividends to fund retirement. This report outlines how to build $5,000 m...